A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, "The LEGEND Study"
Phase of Trial: Phase IV
Latest Information Update: 29 May 2018
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms LEGEND
- Sponsors Genesis Pharma
- 29 May 2018 Last checked against ClinicalTrials.gov record.
- 17 Jan 2017 Status changed from recruiting to completed.
- 11 Dec 2015 New trial record